|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Maintenance of Remission Among Patients With Crohn’s Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped显示文摘 | Edouard Louis Jean–Yves Mary Gwenola Vernier–Massouille Jean–Charles Grimaud Yoram Bouhnik David Laharie Jean–Louis Dupas Hélène Pillant Laurence Picon Michel Veyrac Mathurin Flamant Guillaume Savoye Raymond Jian Martine DeVos Rapha?l Porcher Gilles Paint | 2012 | Gastroenterology2012，，1： | 4 |
| 2 | Neuroflament light and heterogeneity of disease progression in amyotrophic lateral sclerosis:development and validation of a prediction model to improve interventional trials显示文摘Background:Interventional trials in amyotrophic lateral sclerosis(ALS)sufer from the heterogeneity of the disease as it considerably reduces statistical power.We asked if blood neuroflament light chains(NfL)could be used to antici‑pate disease progression and increase trial power.Methods:In 125 patients with ALS from three independent prospective studies-one observational study and two interventional trials-we developed and externally validated a multivariate linear model for predicting disease pro‑gression,measured by the monthly decrease of the ALS Functional Rating Scale Revised(ALSFRS-R)score.We trained the prediction model in the observational study and tested the predictive value of the following parameters assessed at diagnosis:NfL levels,sex,age,site of onset,body mass index,disease duration,ALSFRS-R score,and monthly ALSFRS-R score decrease since disease onset.We then applied the resulting model in the other two study cohorts to assess the actual utility for interventional trials.We analyzed the impact on trial power in mixed-efects models and compared the performance of the NfL model with two currently used predictive approaches,which anticipate disease progression using the ALSFRS-R decrease during a three-month observational period(lead-in)or since disease onset(ΔFRS).Results:Among the parameters provided,the NfL levels(P<0.001)and the interaction with site of onset(P<0.01)contributed signifcantly to the prediction,forming a robust NfL prediction model(R=0.67).Model application in the trial cohorts confrmed its applicability and revealed superiority over lead-in andΔFRS-based approaches.The NfL model improved statistical power by 61%and 22%(95%confdence intervals:54%-66%,7%-29%).Conclusion:The use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could signif‑cantly increase the trial power.NCT00868166,registered March23,2009;NCT02306590,registered December 2,2014. | Simon Witzel Felix Frauhammer† Petra Steinacker David Devos Pierre‑François Pradat Vincent Meininger Stefen Halbgebauer Patrick Oeckl Joachim Schuster Simon Anders Johannes Dorst Markus Otto Albert C.Ludolph | 2021 | Translational Neurodegeneration2021，10，3： | 1 |
| 3 | A new validated analytical method for the determination of tributyltin in water samples at the quantification level set by the European Union 显示文摘 | Devos C David F Sandra P | 2012 | J ChromatograA2012，1261，： | 1 |
| 4 | A new validated analytical method for the determination of tributyltin in water samples at the quantification level set by the European Uinon 显示文摘 | Devos C David F Sandra P | 2012 | Journal of Chromatography A2012，1261，43： | 1 |
| 5 | Trends in comparative genetics and their potential impacts on wheat and barley research显示文摘 | David A. Laurie Katrien M. Devos | 2002 | Plant Molecular Biology (-)2002，，5： | 1 |
| 6 | Platelet microparticles: Detection and assessment of their paradoxical functional roles in disease and regenerative medicine显示文摘 | Thierry Burnouf Hadi Alphonse Goubran Ming-Li Chou David Devos Mirjana Radosevic | 2014 | Blood Reviews2014，，： | 1 |
| 7 | 变化中的家庭医学:来自夏延山Keystone Ⅲ大会的新观点显示文摘美国家庭医学小组于2000年10月在夏延山召开了KeystoneⅢ大会。与会者包括第一代(1970年之前进入,代表专业的创始人),第二代(1970—1990年进入,代表积极建立和推进这一领域的人员)及第三代家庭医学成员(1990年以后进入,代表当时最新的家庭医生)。会议期间,三代成员一起讨论思考过去、现在及家庭医学的未来,我们在其中的角色,以及如何理解现有的及发展中的家庭医生和家庭医学。历经10多年的发展后,由10名第三代成员撰写了本文,反映了他们目前的观点。本刊编辑部特翻译此篇文章,希望对中国的全科医生也有一定的启发和帮助。 | Elizabeth Steiner Erika Bliss Kara Cadwallader Terrence E. Steyer Deborah S. Clements Jennifer E. DeVoe Kenneth Fink Marina Khubesrian Paul Lyons David Weismiller 王静 | 2014 | 中国全科医学2014，17，13： | 0 |
| 8 | New hypertension and diabetes diagnoses following the Affordable Care Act Medicaid expansion显示文摘Objective To assess the Affordable Care Act(ACA)Medicaid expansion’s impact on new hypertension and diabetes diagnoses in community health centres(CHCs).Design Rates of new hypertension and diabetes diagnoses were computed using generalised estimating equation Poisson models and we tested the difference-in difference(DID)pre-ACA versus post-ACA in states that expanded Medicaid compared with those that did not.Setting We used electronic health record data(pre-ACA:1 January 2012-31 December 2013-post-ACA:1 January 2014-31 December 2016)from the Accelerating Data Value Across a National Community Health Center Network clinical data network.We included clinics with≥50 patients contributing to person-time at risk in each study year.Participants Patients aged 19-64 with≥1 ambulatory visit in the study period were included.We then excluded patients who were pregnant during the study period(N=127530).For the hypertension outcome,we excluded individuals with a diagnosis of hypertension prior to the start of the study period,those who had a hypertension diagnosis on their first visit to a clinic or their first visit after 3 years without a visit,and those who had a diagnosis more than 3 years after their last visit(pre-ACA non-expansion N=130973;expansion N=193198;post-ACA non-expansion N=186341;expansion N=251015).For the diabetes analysis,we excluded patients with a diabetes diagnosis prior to study start,on their first visit or first visit after inactive patient status,and diagnosis while not an active patient(pre-ACA non-expansion N=145435;expansion N=198558;post-ACA non-expansion N=215039;expansion N=264644).Results In non-expansion states,adjusted hypertension diagnosis rates saw a relative decrease of 6%,while in expansion states,the adjusted rates saw a relative increase of 7%(DID 1.14,95%CI 1.11 to 1.18).For diabetes diagnosis,adjusted rates in non-expansion states experienced a significant relative increase of 28%and in expansion states the relative increase was 25%;yet these differences were not significant pre-ACA to post-ACA comparing expansion and non-expansion states(DID 0.98,95%CI 0.91 to 1.05).Conclusion There was a differential impact of Medicaid expansion for hypertension and diabetes diagnoses.Moderate increases were found in diabetes diagnosis rates among all patients served by CHCs post-ACA(both in expansion and non-expansion states).These increases suggest that ACA-related opportunities to gain health insurance(such as marketplaces and the Medicaid expansion)may have facilitated access to diagnostic tests for this population.The study found a small change in hypertension diagnosis rates from pre-ACA to post-ACA(a decrease in non-expansion and an increase in expansion states).Despite the significant difference between expansion and non-expansion states,the small change from pre-ACA to post-ACA suggests that the diagnosis of hypertension is likely documented for patients,regardless of health insurance availability.Future studies are needed to understand the impact of the ACA on hypertension and diabetes treatment and control. | Heather Angier Nathalie Huguet David Ezekiel-Herrera Miguel Marino Teresa Schmidt Beverly B Green Jennifer E DeVoe | 2020 | Family Medicine and Community Health2020，8，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员